LIPTIDE
LIVE

Serial Number

79243223

Owner

Nanogenics Limited

Attorney

Thomas W. Cole

Filing Date

Jul 30, 2018

Add to watchlist:

No watchlists yet
View on USPTO

LIPTIDE Trademark

Serial Number: 79243223 • Registration: 6039104

LIPTIDE is a trademark filed by Nanogenics Limited on July 30, 2018. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

Nanogenics Limited (2 trademarks)

2nd Floor, 2 Woodberry Grove
London N120DR , GB

Entity Type: 99

Trademark Details

Filing Date

July 30, 2018

Registration Date

April 28, 2020

Published for Opposition

February 11, 2020

Goods & Services

Pharmaceutical preparations and substances for use in relation to gene therapy used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; chemicals for pharmaceutical use in relation to gene therapy used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; pharmaceuticals and pharmaceutical preparations being nanoparticles for use in relation to gene therapy used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; pharmaceuticals and pharmaceutical preparations containing siRNA for use in relation to gene therapy used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; pharmaceuticals and pharmaceutical preparations containing RNA for use in relation to gene therapy used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; pharmaceuticals and pharmaceutical preparations containing shRNA for use in relation to gene therapy used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; pharmaceuticals and pharmaceutical preparations containing mRNA for use in relation to gene therapy used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; pharmaceuticals and pharmaceutical preparations containing DNA for use in relation to gene therapy used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; drug delivery agents being made from lipids, liposomes or peptides in the form of nanoparticles that facilitate the delivery of a wide variety of pharmaceuticals; pharmaceuticals and pharmaceutical preparations containing lipids, liposomes or peptides for treatments in the form of gene therapy used in the treatment of cancer; drug delivery agents in the form of nanoparticles that facilitate the delivery of a wide variety of pharmaceuticals; drug delivery agents that facilitate the delivery of pharmaceuticals and pharmaceutical preparations in the form of nanoparticles; intravenous fluids used for rehydration, nutrition and the delivery of pharmaceutical preparations; pharmaceutical and drug delivery agents for use in relation to the delivery of siRNA, shRNA, mRNA, RNA, DNA or other genetic material in the form of nanoparticles; preparations for detecting genetic predispositions for medical purposes; pharmaceuticals and pharmaceutical preparations for use in gene therapy in the form of nanoparticles used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; drug delivery agents for use in gene therapy in the form of nanoparticles that facilitate the delivery of a wide variety of pharmaceuticals; drug delivery agents being nanoparticles in the form of an artificial virus that facilitate the delivery of a wide variety of pharmaceuticals; pharmaceutical and natural remedies for use in relation to gene therapy used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; medical preparations for use in relation to gene therapy used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; biochemical preparation for medical purposes for treatments in the form of gene therapy used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; biological preparations for medical purposes for use in relation to gene therapy used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; reagents for medical use; reagents for use in medical genetic testing; anti-cancer preparations; anti-cancer drugs; compounds for treating cancer; biopharmaceuticals for the treatment of cancer; anti-cancer preparations of chemical origin; anti-cancer preparations of plant origin; anti-cancer preparations of microbial origin; pharmaceutical preparations for the treatment of cancer; pharmaceutical products for the treatment of cancer; biological preparations for the treatment of cancer; anti-cancer preparations from hormones and antagonists; pharmaceutical preparations and substances for the prevention of cancer; chemotherapeutics for use in the treatment of cancer; pharmaceutical preparations for use in chemotherapy for the treatment of cancer; pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations for the treatment and prevention of tumours

Filing History

COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Apr 28, 2025 REM3
NEW REPRESENTATIVE AT IB RECEIVED
Apr 19, 2024 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Sep 26, 2020 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Sep 8, 2020 FICS
FINAL DISPOSITION PROCESSED
Sep 5, 2020 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jul 28, 2020 FICR
REGISTERED-PRINCIPAL REGISTER
Apr 28, 2020 R.PR
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Apr 3, 2020 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Mar 18, 2020 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Mar 18, 2020 OPNR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 11, 2020 NPUB
PUBLISHED FOR OPPOSITION
Feb 11, 2020 PUBO
NOTIFICATION PROCESSED BY IB
Feb 7, 2020 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jan 22, 2020 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Jan 22, 2020 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jan 22, 2020 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 3, 2020 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 26, 2019 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 26, 2019 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Dec 26, 2019 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Jun 28, 2019 GNFN
FINAL REFUSAL E-MAILED
Jun 28, 2019 GNFR
FINAL REFUSAL WRITTEN
Jun 28, 2019 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 7, 2019 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 7, 2019 CRFA
ASSIGNED TO LIE
Jun 3, 2019 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 29, 2019 TROA
NEW REPRESENTATIVE AT IB RECEIVED
Apr 11, 2019 NREP
REFUSAL PROCESSED BY IB
Dec 28, 2018 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Dec 7, 2018 RFCS
REFUSAL PROCESSED BY MPU
Dec 7, 2018 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Nov 24, 2018 RFCR
NON-FINAL ACTION WRITTEN
Nov 23, 2018 CNRT
ASSIGNED TO EXAMINER
Nov 15, 2018 DOCK
APPLICATION FILING RECEIPT MAILED
Oct 23, 2018 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 19, 2018 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Oct 18, 2018 REPR